首页> 外文会议>International AIDS Conference >Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life

【24h】

Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

In patients with HCV mono-infection, sustained virological response (SVR) is associated with improved health-related quality of life (HRQOL). However, the relationship between SVR and HRQOL in patients with HCV/HIV coinfection is not known.

机译：在HCV单声道感染患者中，持续的病毒学反应（SVR）与改善的健康状生活质量（HRQOL）有关。然而，HCV / HIV辛纤维患者的SVR和HRQOL之间的关系尚不清楚。

著录项

来源
《International AIDS Conference》|2004年||共2页
会议地点
作者
D.T. Dieterich; M. Rodriguez Torres; J.K. Rockstroh;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类获得性免疫缺陷综合征（AIDS艾滋病）;
关键词
Hepatitis C virus; Infection as complication of medical care; HIV; Health;

机译：丙型肝炎病毒;感染作为医疗保健的并发症;艾滋病毒;健康;
入库时间 2022-08-20 19:36:15

相似文献

外文文献
中文文献
专利

1. Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin. [J] . Rodriguez Torres M, Torriani F, Rockstroh J, HIV clinical trials . 2010,第1期

机译：治疗初期病毒下降的程度预示了接受聚乙二醇干扰素α-2a和利巴韦林治疗的HCV-HIV合并感染患者的持续病毒学应答。
2. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program [J] . Bruno S., Bollani S., Zignego A. L., Journal of viral hepatitis. . 2015,第5期

机译：在治疗第8周时未检测到HCV-RNA导致在接受HCV G1治疗的晚期肝病患者中高度持续的病毒学应答：国际意大利/西班牙Boceprevir / Peginterferon / Ribavirin姓名患者计划
3. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin [J] . Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, International Journal of Medical Sciences . 2016,第4期

机译：在治疗结束后第24周持续的病毒学应答是用聚乙二醇干扰素加利巴韦林治疗的HCV NS3 / 4A蛋白酶抑制剂治疗的真实HCV感染患者中治疗结果的更好预测指标
4. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
5. Baseline Toronto HCC Risk Index (THRI) and Albumin Predict Low Risk of Hepatocellular Carcinoma (HCC) after Sustained Virological Response (SVR) in HCV Infection [D] . Lau, Jason. 2019

机译：基线多伦多HCC风险指数（THRI）和白蛋白预测HCV感染持续病毒响应（SVR）后肝细胞癌（HCC）的低风险
6. A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin [O] . Tarik Asselah, Alex J. Thompson, Robert Flisiak, -1

机译：一种选择模型的HCV基因型3型慢性感染患者对聚乙二醇干扰素Alfa-2a /利巴韦林具有持续病毒学应答的高可能性的预测模型
7. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program [O] . Bruno, S, Bollani, S, Zignego, AL, 2015

机译：在治疗第8周时未检测到HCV-RNA会在经历过HCV G1治疗的晚期肝病患者中导致高度持续的病毒学应答：国际意大利/西班牙Boceprevir / Peginterferon /利巴韦林命名患者计划

Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life

摘要

著录项

相似文献

相关主题

期刊订阅